The estimated Net Worth of Michael Catelani is at least $524 Mille dollars as of 7 June 2024. Mr Catelani owns over 6,250 units of Anixa Biosciences stock worth over $108,802 and over the last 8 years he sold ANIX stock worth over $0. In addition, he makes $415,698 as Pres, COO e CFO & Corp. Sec. at Anixa Biosciences.
Sign up
Mr MBA ANIX stock SEC Form 4 insiders trading
Mr has made over 5 trades of the Anixa Biosciences stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 6,250 units of ANIX stock worth $15,000 on 7 June 2024.
The largest trade he's ever made was buying 6,250 units of Anixa Biosciences stock on 7 June 2024 worth over $15,000. On average, Mr trades about 786 units every 75 days since 2016. As of 7 June 2024 he still owns at least 35,211 units of Anixa Biosciences stock.
You can see the complete history of Mr Catelani stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Michael J. Catelani CPA, MBA biography
Michael J. Catelani CPA, MBA is the Pres, COO, CFO & Corp. Sec. at Anixa Biosciences.
What is the salary of Mr MBA?
As the Pres, COO e CFO & Corp. Sec. of Anixa Biosciences, the total compensation of Mr MBA at Anixa Biosciences is $415,698. There are 2 executives at Anixa Biosciences getting paid more, with Dr. Amit Kumar Ph.D. having the highest compensation of $720,865.
How old is Mr MBA?
Mr MBA is 54, he's been the Pres, COO e CFO & Corp. Sec. of Anixa Biosciences since . There are 7 older and 2 younger executives at Anixa Biosciences. The oldest executive at Anixa Biosciences, Inc. is Lewis Titterton, 75, who is the Lead Independent Director.
What's Mr MBA's mailing address?
Michael's mailing address filed with the SEC is C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,, CA, 95118.
Insiders trading at Anixa Biosciences
Over the last 6 years, insiders at Anixa Biosciences have traded over $0 worth of Anixa Biosciences stock and bought 834,156 units worth $2,822,805 . The most active insiders traders include Amit Kumar, Lewis H Jr Titterton e Arnold M Baskies. On average, Anixa Biosciences executives and independent directors trade stock every 31 days with the average trade being worth of $78,894. The most recent stock trade was executed by Lewis H Jr Titterton on 30 July 2024, trading 27,226 units of ANIX stock currently worth $84,128.
What does Anixa Biosciences do?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
What does Anixa Biosciences's logo look like?
Complete history of Mr Catelani stock trades at Anixa Biosciences
Anixa Biosciences executives and stock owners
Anixa Biosciences executives and other stock owners filed with the SEC include:
-
Dr. Amit Kumar Ph.D.,
Chairman, Pres & CEO -
Amit Kumar,
Chairman of the Board, President, Chief Executive Officer -
Michael J. Catelani CPA, MBA,
Pres, COO, CFO & Corp. Sec. -
Michael J. Catelani,
COO, CFO & Corp. Sec. -
Michael Catelani,
Chief Financial Officer, Chief Operating Officer -
Lewis Titterton,
Lead Independent Director -
John Monahan,
Independent Director -
Emily Gottschalk,
Independent Director -
David Cavalier,
Independent Director -
Arnold Baskies,
Independent Director -
Thomas Schlumpberger,
Executive Vice President -
Dr. Pamela D. Garzone Ph.D.,
Chief Devel. Officer -
John Roop,
Sr. VP of Engineering